Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Gilead Sciences: Clinical Trials & FDA Approval Profile

Gilead Sciences (Foster City, CA) sponsors 123 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 60 active protocols (17 recruiting now), 31 completed protocols, and 38 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)26.0%
Median Closed Enrollment vs National (145 pts)175 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Gilead Sciences
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)123
Active Pipeline (Recruiting Now)60 (17)
Completed vs Stopped Early31 / 32 (26.0%)
Median Closed Actual Enrollment175 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals38 (14 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Gilead Sciences
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA27
Hospital Clinic de BarcelonaBarcelona25
Stanford Health Care and Stanford Cancer InstituteStanford, CA25

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Gilead Sciences
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07708727Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentPhase II/IIIRECRUITING
NCT07682961Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on OralPhase IIIRECRUITING
NCT07645287A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Phase IIRECRUITING
NCT07527858Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerPhase IIRECRUITING
NCT06051617Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Gilead Sciences Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI